The United Kingdom and the United States have reached a landmark commercial pact that will maintain no import taxes on British medicine products being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on medicines through the public health system. This pledge secures that duties on these vital products will stay at zero for a duration of the next three years.
This development follows recent warnings to significantly raise import taxes on patented pharmaceutical products, with figures floated up to double the cost.
"This arrangement with the Britain strengthens the global environment for innovative medicines and introduces much-needed balance to U.S.–U.K. drug exports," a statement declared.
Commercial Significance
Medicines represent one of the the United Kingdom's largest exports to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to the third quarter, the UK sold drugs valued at £11.1bn to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This guarantee protects work, increases investment and sets the stage for the UK to become a international leader for medical research," a government official stated.
Specific UK Commitments
The pact involves several specific pledges from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to raise total public funding on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to stay within budget will be capped at 15%. Last year, repayments topped twenty percent.
Broader Context
This agreement follows a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were exacerbated by claims that American patients were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or cancelled, while substantial expansions have been announced toward American operations.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the previous ten-year period.
